A clinical trial has recently been launched to evaluate the safety and efficacy of the antiviral drug remdesivir plus the anti-inflammatory drug baricitinib for treatment of SARS-CoV-2 infection. The clinical trial, which is also sponsored by NIAID, represents the next phase of NIAID’s Adaptive COVID-19 Treatment Trial, or ACTT. This new trial, known as ACTT2, will recruit participants with confirmed SARS-CoV-2 infection and evidence of lung involvement. Participants will be randomized to receive either remdesivir plus baricitinib, or remdesivir alone. Among other outcomes, investigators will determine if there are significant differences in recovery time across the two treatment groups. To learn more about the clinical trial, please visit the study site on ClinicalTrials.gov, or search by identifier NCT04280705.